Hepta's AI Reads Liver Biology From a Routine Blood Draw, Achieving MRE-Level Accuracy at Finding Patients for Newly Approved MASH Drugs

Hepta, a liquid biopsy company focused on liver disease, today announced research demonstrating how its LiquidTransformer ...